Gerontology/Geriatrics Topic Homepage

Learning Zones

,Prostate Cancer Learning Hub

Prostate cancer is the third most frequently diagnosed cancer in Europe and the most common cancer among European men,1 making it a major cause of morbidity. Risk factors for prostate cancer include, increasing age, genetic susceptibility, glucose intolerance and environmental factors.2

The Prostate Cancer Learning Hub has been designed with the busy healthcare professional in mind. The resource conveniently organises a range of up-to-date education content, reference materials and decision support tools, all focussing on prostate cancer.

The disease awareness section provides you with access to a Prostate Cancer Knowledge Centre, which has been developed to provide you with easy to digest best practice guidance for the treatment and management of patients with prostate cancer. In addition access to editorials of key journal publications, an events calendar, video channel, patient materials and interactive healthcare professionals tools are also available.


  1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403. EUCAN fact sheet. Estimated incidence, mortality & prevalence, 2012.
  2. Tewari R, Rajender S, Natu SM et al. Diet, obesity, and prostate health: are we missing the link? J Androl 2012;33:763-776.



The Anti-Coagulation Video Channel* is intended for primary care practitioners and specialists involved in the treatment and follow up care of patients with atrial fibrillation (AF) or venous thromboembolism (VTE). It provides an overview of how to prevent stroke and systemic embolism in nonvalvular AF patients and how to prevent and treat VTE.

Users can expect to find the following videos readily available on the video channel with regular updates:

  • The benefits of dabigatran in preventing stroke in atrial fibrillation patients
    (Hans-Christoph Diener, Gregory YH Lip and John Eikelboom)
  • Dabigatran for the treatment and prevention of DVT and PE
    (Samuel Z Goldhaber)
  • The safety profile of dabigatran
    (Hans-Christoph Diener, John Eikelboom and Jeffrey Weitz)

Healthcare professionals should return often to avoid missing out on new content.

*The Anti-Coagulation Video Channel has been supported by an educational grant from Boehringer Ingelheim, who provided the videos, and is intended for healthcare professionals outside the USA, Canada and UK.

,COPD Knowledge Centre

COPD affects an estimated 210 million people worldwide and is now the 3rd leading cause of death (WHO 2015). Patients with Chronic Obstructive Pulmonary Disease (COPD) will rank as the fifth leading cause of disability in 2030, accounting for almost 4% of total disability-adjusted life years (DALYs) lost worldwide.1 Many patients with COPD report that the symptoms of COPD are at their worst in the morning and have a major impact on their quality of life.2

The COPD Knowledge Centre has been designed to provide healthcare professionals with free access to educational materials and disease awareness information. This includes epidemiology, pathophysiology and COPD symptoms. Users will also discover the latest guidelines for the diagnosis, treatment and management of the disease.

COPD specific resources such as videos, guidelines, infographics, materials for your patients, upcoming events and useful websites are available for you. Educational slide decks and interactive presentations from ATS 2014 and 2015 are also available.


  1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and prevention of COPD. 2015

  2. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009;25:2043-2048; Curr Med Res Opin 2012;28:1405 [Erratum].

Heart Failure

Heart Failure is a progressive chronic disorder that results in the inability of the heart to pump blood efficiently to the body’s tissues.

Chronic heart failure is an increasing public health problem; the growing prevalence in industrialised countries means that 1-2% of the adult population of these countries are now thought to have chronic heart failure.1-3 Estimates suggest that the prevalence in Europe, USA and Japan could increase by approximately 16.5% over the next ten years.4

The prevalence of post-myocardial infarction heart failure is less well known as it is difficult to distinguish between pre-existing and incident heart failure. However current estimates suggest that approximately 1 in 5 patients hospitalised with an acute coronary syndrome either present with heart failure or develop heart failure during their hospital stay.5

Many of the signs and symptoms of heart failure are non-specific and vary in severity depending on the disease class. The most common of these are breathlessness, fatigue, exercise intolerance, and fluid retention as evidenced by ankle swelling, peripheral oedema, and an elevated jugular venous pressure.6

Due to the non-specific nature of symptoms, the diagnosis of heart failure can be difficult. Tests can include echocardiogram, ECG, chest X-ray, laboratory tests. Following a positive diagnosis heart failure is classified into functional classes that relate to disease severity.

Management of heart failure involves lifestyle modifications, pharmacological treatment and occasionally surgery. In patients with chronic heart failure, optimal therapy involves treatment with diuretics, ACE inhibitors, certain β-blockers and a mineralocorticoid receptor antagonist.

The Heart Failure Knowledge Centre brings together current information related to chronic heart failure and post-myocardial infarction, including:

  • Epidemiology
  • Symptoms and Diagnosis
  • Classification
  • Treatment Options
Enter the Heart Failure Knowledge Centre


  1. Zannad F, et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Journal of the American College of Cardiology 1999; 33(3):734-742.
  2. Cowie MR, et al. The epidemiology of heart failure. European Heart Journal 1997;18(2):208-225.
  3. Mosterd A, Hoes A. Clinical epidemiology of heart failure. Heart 2007; 93:1137-1146.
  4. Decision Resources. Chronic Heart Failure. Cardium Study No.4 A Pharmacor Service. 2008.
  5. Steg PG, Dabbous OH, et al. Determinants and prognostic impact of heart failure complicating acutecoronary syndromes. Observations from the Global Registry of Acute Coronary Events (GRACE). Circulation2004;109:494-9.
  6. NICE Clinical Guideline No 108. Chronic Heart Failure. National clinical guideline for diagnosis and management in primary and secondary care. 2010.

The Hypogonadism Knowledge Centre is a resource for healthcare professionals involved in the diagnosis, treatment and monitoring of patients with the condition.

The publications digest section of this resource is regularly updated with analysis and commentary on recent scientific articles related to male hypogonadism. There are currently over 50 articles available in the publications digest area, which can be filtered by year or by the following comorbidities:

  • Diabetes
  • Obesity
  • Cardiovascular
  • Mood and behaviour
  • Sexual health

Latest News

Medical Videos

Ask The Geriatrician - The Physiology of Ageing
Ask The Geriatrician - The Physiology of Ageing

Recent Drug Updates

Medical Journal Abstracts on Gerontology/Geriatrics

Mild cognitive impairment in Parkinson's disease: Diagnosis and progression to dementia.

6 days ago -  Mild cognitive impairment in Parkinson's disease: Diagnosis and progression to dementia.

INTRODUCTION: Mild cognitive impairment is common in nondemented Parkinson disease patients (PD-MCI) and is considered as a risk factor for dementia (PDD). Recently, the Movement Disorder Society ...

Relation of Central Arterial Stiffness to Incident Heart Failure in the Community.

8 days ago -  Relation of Central Arterial Stiffness to Incident Heart Failure in the Community.

BACKGROUND: Arterial stiffness, pressure pulsatility, and wave reflection are associated with cardiovascular disease. Left ventricular function is coupled to proximal aortic properties, but the ...

Clinical Guidelines

European Stroke Organisation (ESO) guidelines for the management of temperature in patients with acute ischemic stroke

Jul 2015

Hyperthermia is a frequent complication in up to 50% of patients with acute ischemic stroke, and it..

... was shown to be associated with a poor outcome. On the other end, therapeutically induced hypothermia has shown promising potential in patients with hypoxic encephalopathy and in animal models of focal cerebral ischemia. This document presents the ESO guidelines on temperature management in patients with acute ischemic stroke. The aim of this Guideline document is to assist physicians treating patients with acute ischemic stroke in their clinical decisions with regard to the management of temperature.

Lower urinary tract symptoms: The management of lower urinary tract symptoms in men

Jun 2015

Lower urinary tract symptoms (LUTS) in men are best categorised into voiding, storage or..

... post-micturition symptoms to help define the source of the problem. Voiding symptoms include weak or intermittent urinary stream, straining, hesitancy, terminal dribbling and incomplete emptying. Storage symptoms include urgency, frequency, urgency incontinence and nocturia. The major post-micturition symptom is post-micturition dribbling, which is common and bothersome. Although LUTS do not usually cause severe illness, they can considerably reduce men's quality of life, and may point to serious pathology of the urogenital tract.

LUTS are a major burden for the ageing male population. Age is an important risk factor for LUTS and the prevalence of LUTS increases as men get older. Bothersome LUTS can occur in up to 30% of men older than 65 years. This is a large group potentially requiring treatment.

Because uncertainty and variation exist in clinical practice, this guideline gives clear recommendations on diagnosing, monitoring and treating LUTS.

Online CME

e-LfH Dementia

Dementia is becoming increasingly prevalent, both due to our ageing population and improved recognition of the condition. However, the nature of dementia means that managing the condition can pose unique...

Anaemia in old age: common presentations

After completing this module you should know how to: take a history and examine an elderly patient with anaemia, diagnose the common causes of anaemia in old age, and treat...

Clinical Trials

Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease.


This is a Phase 3, 52-week, open-label, flexible-dose, multinational, multicenter study to evaluate the safety and tolerability of istradefylline 20 or 40 mg/d in subjects with moderate to severe PD ...

Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease

Tue 01 Sep 2015

This is a global Phase III, randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The protocol is designed to determine whether ALZT-OP1 combination ...

Back to top